Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24488470 | 0.77 | ALDH1A1 (0.36) | GAANPC1ALDH1A1CYP3A4TSHR | |
| SCHEMBL29644394 | 0.77 | POLB (0.44) | GAANPC1ALDH1A1ERN1CYP3A4 | |
| SCHEMBL16831742 | 0.77 | POLB (0.44) | GAANPC1ALDH1A1ERN1CYP3A4 | |
| SCHEMBL16198301 | 0.75 | GAA (0.48) | GAANPC1ALDH1A1ERN1CYP3A4 | |
| SCHEMBL10945773 | 0.75 | GAA (0.48) | GAANPC1ALDH1A1ABL1ERN1 | |
| SCHEMBL14531753 | 0.74 | CYP3A4 (0.45) | GAAALDH1A1ABL1CYP3A4TSHR | |
| SCHEMBL21307506 | 0.73 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1KDM4E | |
| SCHEMBL17744292 | 0.72 | ERN1 (0.55) | GAANPC1ALDH1A1ABL1ERN1 | |
| SCHEMBL17057702 | 0.72 | CYP3A4 (0.34) | GAAALDH1A1ABL1CYP3A4TSHR | |
| SCHEMBL30627393 | 0.72 | CYP3A4 (0.34) | GAAALDH1A1ABL1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301036-B2 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | GCGR, GLP1R, GCG | GAA 449/4885NPC1 2228/4885ALDH1A1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.